Common all-grade adverse events were diarrhea (68.8%), nausea (64.6%), and fatigue (52.1%) for DHP107 and fatigue (47.6%), peripheral neuropathy (42.9%), and alopecia (42.9%) for IV paclitaxel.<h4>Conclusion</h4>DHP107 is a tolerable and feasible treatment for patients with recurrent or metastatic HER2-negative breast cancer, with similar efficacy and safety to IV paclitaxel.<h4>Clinicaltrials</h4>gov no: NCT03326102; date of registration October 19, 2017. The gene discussed is ERBB2; the disease is peripheral neuropathy.